8-K: Revelation Biosciences Implements 1-for-3 Reverse Stock Split to Regain Nasdaq Compliance

Revelation Biosciences, Inc. has implemented a 1-for-3 reverse stock split effective July 7, 2025, to increase its share price and regain compliance with Nasdaq's minimum bid requirement, while also providing an update on its clinical study progress.

Summary

• Revelation Biosciences, Inc. effected a 1-for-3 reverse stock split of its common stock, effective 12:01 a.m. Eastern Standard Time on July 7, 2025.
• The reverse stock split was approved by stockholders at the Annual Meeting on June 25, 2025, granting discretionary authority to the board of directors.
• Each three shares of common stock outstanding prior to the split automatically converted into one share, without changing the par value per share of $0.001.
• Approximately 1,534,599 shares of common stock were issued and outstanding immediately after the reverse stock split became effective on July 7, 2025.
• Fractional shares resulting from the Reverse Stock Split were rounded down to the nearest whole share, as detailed in the Certificate of Amendment and press release.
• Proportionate adjustments were made to all then-outstanding equity awards and warrants (except Class D, G, and H Common Stock Warrants which have price reset features) with respect to the number of shares and exercise price.
• The number of shares of common stock available for issuance under the company's equity incentive plans were proportionately adjusted.
• The new CUSIP number for common stock following the Reverse Stock Split is 76135L705.
• The company's common stock began trading on a post-split basis under the existing trading symbol, REVB, when the market opened on July 7, 2025.
• The reverse stock split is intended to increase the market price per share of the company's common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market.
• The ongoing PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete enrollment in July 2025, with topline data expected shortly after.

Sentiment

Score: 3

Explanation: The reverse stock split is a necessary action to maintain Nasdaq listing, but it signals underlying stock price weakness. While clinical study progress is positive, the overall sentiment is tempered by the compliance issue and the cosmetic nature of the split.

Positives

• The company is taking proactive action to regain compliance with Nasdaq's minimum bid price requirement, which is crucial for maintaining its listing and market visibility.
• The PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete enrollment in July 2025, with topline data anticipated shortly thereafter, indicating progress in its clinical development programs.

Negatives

• The necessity of a reverse stock split indicates that the company's stock price has fallen below Nasdaq's minimum bid requirement, signaling potential underlying financial or operational challenges.
• While necessary for listing, reverse splits are often viewed by investors as a cosmetic fix rather than a fundamental improvement in company performance.
• Fractional shares resulting from the reverse stock split were rounded down to the nearest whole share, which can result in a loss for affected stockholders. This contradicts the main 8-K filing which stated fractional shares would be rounded up, but is consistent with the Certificate of Amendment and press release.

Risks

• The ability of Revelation to meet its financial and strategic goals, due to, among other things, competition.
• The ability of Revelation to grow and manage growth profitability and retain its key employees.
• The possibility that Revelation may be adversely affected by other economic, business, and/or competitive factors.
• Risks relating to the successful development of Revelation's product candidates.
• The ability to successfully complete planned clinical studies of its product candidates.
• The risk that clinical studies may not fully enroll or enrollment will take longer than expected.
• Risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from clinical studies.
• Changes in applicable laws or regulations.
• The outcome of clinical data, including whether the results are positive or can be replicated.
• The outcome of data collected, including whether the results and/or correlation can be replicated.
• The timing, costs, conduct, and outcome of other clinical studies.
• The anticipated treatment of future clinical data by regulatory authorities (FDA, EMA), including whether such data will be sufficient for approval.
• The success of future development activities for its product candidates.
• Potential indications for which product candidates may be developed.
• The ability of Revelation to maintain the listing of its securities on NASDAQ.
• The expected duration over which Revelation's balances will fund its operations.

Future Outlook

The company expects its PRIME Phase 1b clinical study of Gemini in CKD patients to complete enrollment in July 2025, with topline data anticipated shortly thereafter. The company also aims to maintain its Nasdaq listing by increasing its market price per share through the reverse stock split.

Management Comments

• Revelation Biosciences Inc. announced that on July 7, 2025, the company would implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025.
• The reverse stock split is intended to increase the market price per share of the company's common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market.
• Proportionate adjustments will be made to the conversion and exercise prices of the company's warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the company's equity incentive plans.
• The ongoing PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete enrollment this month and topline data expected shortly after.

Industry Context

Reverse stock splits are a common strategy employed by small-cap biotechnology and life sciences companies to meet stock exchange listing requirements, particularly minimum bid price rules. This action by Revelation Biosciences aligns with a broader trend among companies facing similar challenges, aiming to improve stock liquidity and investor perception, although it does not address underlying business fundamentals.

Comparison to Industry Standards

• The 1-for-3 reverse stock split ratio is within the typical range seen in the biotech industry for companies seeking to regain Nasdaq compliance, which often ranges from 1-for-2 to 1-for-50 or higher depending on the severity of the price deficiency.
• The immediate adjustment of equity awards and warrants is standard practice to maintain their proportionate value and exercise terms post-split.
• The rounding down of fractional shares, as stated in the Certificate of Amendment and press release, is a common practice in reverse stock splits, though some companies opt for rounding up or cash payments for fractional shares.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the 1-for-3 reduction in the number of shares held, with fractional shares rounded down. The goal is to maintain Nasdaq listing, which benefits shareholders by preserving liquidity and visibility.
• Employees (holding equity awards): Equity awards (restricted stock units, stock options) and shares available under equity incentive plans were proportionately adjusted to reflect the reverse split, maintaining their intrinsic value.
• Warrant Holders: Warrants were proportionately adjusted in terms of shares and exercise price, except for Class D, G, and H warrants which have price reset features based on VWAP.

Next Steps

• Completion of enrollment for the PRIME Phase 1b clinical study of Gemini in CKD patients in July 2025.
• Release of topline data for the PRIME Phase 1b clinical study shortly after enrollment completion.
• Continued trading on Nasdaq under the existing symbol REVB on a post-split basis.

Key Dates

Recommendation

Keywords

Revelation Biosciences, REVB, Reverse Stock Split, Nasdaq Compliance, Clinical Study, Gemini, CKD, Biotech, Life Sciences, SEC Filing, 8-K, Stock Market, Warrants, Equity Awards, Corporate Governance